Breast Cancer | Specialty

The OncFive: Top Oncology Articles for the Week of 2/2

February 8th 2025

Encorafenib combination boosts survival in BRAF V600E+ mCRC, pertuzumab biosimilar BLA is under review for HER2+ breast cancer, and more from OncLive.

Advanced Breast Cancer at Diagnosis Linked to 10% Higher CVD Risk

February 7th 2025

Kevin T. Nead, MD, MPhil, details findings on the association between prevalent CVD and breast cancer and next steps for investigating the connection.

Targeted Therapies in HR+/HER2– Breast Cancer

February 7th 2025

CLDN6-Directed Agents Generate Encouraging Early Activity in Solid Tumors

February 5th 2025

Manish R. Patel, MD, and Gottfried E. Konecny, MD, detail findings from studies evaluating CLDN6-directed agents that showed signals of promising efficacy and tolerability.

Proactive AE Management and Prophylactic Strategies With TADCs in Breast Cancer

February 5th 2025

Panelists discuss how trastuzumab deruxtecan’s (T-DXd's) key adverse events (AEs) include interstitial lung disease, neutropenia, and nausea/fatigue, emphasizing the importance of proactive monitoring, early intervention through coordinated multidisciplinary care, and comprehensive patient education with clear communication channels for reporting symptoms.

Patient-Reported Outcomes and Quality of Life Data With T-DXd in HER2-(Ultra) Low mBC

February 5th 2025

Panelists discuss how trastuzumab deruxtecan (T-DXd) demonstrated favorable patient-reported outcomes and quality of life measures in HER2-low hormone receptor-positive metastatic breast cancer patients in DESTINY-Breast06, suggesting it could be a well-tolerated therapeutic option that maintains patients' daily functioning while providing clinical benefit.

Dr Winer on Considerations for Inavolisib Plus Palbociclib and Fulvestrant in PIK3CA-Mutated HR+/HER2– Breast Cancer

February 4th 2025

Eric Winer, MD, discusses considerations for inavolisib plus palbociclib with fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative breast cancer.

Emerging Data of Additional SERDs in Metastatic Breast Cancer

February 4th 2025

Panelists discuss recent data on other selective estrogen receptor degraders (SERDs) and their implications in the treatment of HR+/HER2– breast cancer.

Clinical Findings of Elacestrant, an Oral SERD for ER+/HER2– Metastatic Breast Cancer

February 4th 2025

Panelists discuss the clinical findings of elacestrant, an oral selective estrogen receptor degrader (SERD), for the treatment of ER+/HER2– metastatic breast cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for January 2025

February 3rd 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in January 2025 spanning tumor types.

Dr Bardia on the FDA Approval of Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer

February 3rd 2025

Aditya Bardia, MD, MPH, FASCO, discusses the FDA approval of Dato-DXd for pretreated, hormone receptor–positive, HER2-negative metastatic breast cancer.

A Road Map for Change Report Provides a Guide to Elevate Breast Cancer Care

February 3rd 2025

Coauthor of the Lancet Breast Cancer Commission report, Reshma Jagsi, MD, DPhil, details the 6 themes of the evidence-based plan aimed to address challenges in the field.

Impact of In-House Testing on Improved Cancer Care: Timely Decisions and Enhanced Treatment Accuracy

February 3rd 2025

Panelists discuss how in-house laboratory testing has demonstrated significant advantages in patient care through rapid turnaround times and immediate decision-making capabilities. Emergency departments have seen notably improved outcomes when critical tests like cardiac markers and blood gases are performed on-site, enabling faster treatment initiation for acute conditions. For example, rapid troponin testing in-house allows for immediate cardiac intervention decisions, while stat electrolyte panels enable quick medication adjustments for critical patients. Additionally, on-site therapeutic drug monitoring helps clinicians make real-time dosing modifications, which is particularly beneficial for antibiotics and anticoagulation therapy.

Enhancing Multidisciplinary Coordination and Treatment Planning Through In-House Testing

February 3rd 2025

Panelists discuss how in-house testing facilities significantly enhance multidisciplinary coordination by enabling rapid result turnaround and real-time treatment adjustments. This streamlined process facilitates immediate care planning among specialists, leading to faster clinical decisions and reduced wait times. Studies demonstrate that on-site testing correlates with improved patient outcomes through earlier interventions, decreased length of stay, and enhanced treatment monitoring, ultimately supporting more efficient and responsive patient care delivery.

The OncFive: Top Oncology Articles for the Week of 1/26

February 1st 2025

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

Datopotamab Deruxtecan Wins CHMP Positive Opinion for Previously Treated HR+ Breast Cancer

January 31st 2025

Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.

The ADC OQY-3258 Demonstrates Early Efficacy in Multiple Breast Cancer Subtypes

January 30th 2025

OQY-3258 (ESG401) showed preliminary efficacy in multiple breast cancer subtypes, including TNBC and HR+/HER2- breast cancer.

Emerging Data and Treatment Considerations in HER2 Ultralow Breast Cancer

January 29th 2025

Panelists discuss how emerging data on HER2-ultralow breast cancer is informing treatment decisions, particularly regarding the potential role of trastuzumab deruxtecan, while acknowledging the need for careful patient selection and consideration of traditional treatment sequences.

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

January 29th 2025

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.

Inavolisib Plus Palbociclib/Fulvestrant Shows OS Benefit in Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Breast Cancer

January 28th 2025

Inavolisib plus palbociclib/fulvestrant improved OS vs palbociclib/fulvestrant alone in PIK3CA-mutated, HR-positive, HER2-negative, advanced breast cancer.